Immunogenicity and Safety of Hepatitis B vaccine with a Toll-like Receptor 9 Agonist Adjuvant (HEPLISAV-B) in HBV Vaccine-naive People with HIV.

作者：K. Marks, M. Kang, T. Umbleja, A. Avihingsanon, P. Sugandhavesa, A. Cox, K. Vigil, H. Perazzo, J. Price, L. Katsidzira, C. Vernon, Beverly L Alston-Smith, K. Sherman · 发表于：Clinical Infectious Diseases · 年份：2023 · DOI：10.1093/cid/ciad201 · 被引用次数：29 · 研究领域：Medicine

In this international, multicenter open-label study (ACTG A5379) of HepB-CpG vaccine in people with HIV without prior Hepatitis B Virus (HBV) vaccination, all 68 participants achieved HBV seroprotective titers after the 3-dose series in the primary analysis. No unexpected safety issues were observed.